Skip to main content
. 2006 Jul 25;95(3):266–271. doi: 10.1038/sj.bjc.6603279

Figure 3.

Figure 3

Progression-free survival of patients with high-risk endometrial carcinoma (stage IcG3, IIG3 with myometrial invasion >50%, and III) receiving adjuvant radiotherapy (Radio) or chemotherapy (Chemio). Five-year progression-free survival was 63% and 63%.